Keyword: Recursion Pharmaceuticals
Machine learning-powered drug discoverer Recursion Pharmaceuticals has secured $121 million in new financing for its artificial intelligence programs.
The appointment ends a 20-year stint at Theravance Biopharma and its parent company that culminated in Sharath Hegde rising to head of research.
Genomics, bioelectronics and artificial intelligence are clear themes among FierceMedTech's 2017 Fierce 15 companies.
Recursion Pharmaceuticals looks to step up its artificial intelligence-enabled drug discovery activities and pivot away from the relatively simple job of repurposing meds.
When we were compiling this year’s crop of Fierce 15 companies, some clear themes stood out. Genomics. Bioelectronics. Artificial intelligence. But while multiple companies are working to improve the use of these technologies, there runs a deeper current: making care more accessible.